Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The theory of cancer stem cells (CSCs) proposes that the different cells within a tumor, as well as metastasis deriving from it, are originated from a single subpopulation of cells with self-renewal and differentiation capacities. These cancer stem cells are supposed to be critical for tumor expansion and metastasis, tumor relapse and resistance to conventional therapies, such as chemo- and radiotherapy. The acquisition of these abilities has been attributed to the activation of alternative pathways, for instance, WNT, NOTCH, SHH, PI3K, Hippo, or NF-κB pathways, that regulate detoxification mechanisms; increase the metabolic rate; induce resistance to apoptotic, autophagic, and senescence pathways; promote the overexpression of drug transporter proteins; and activate specific stem cell transcription factors. The elimination of CSCs is an important goal in cancer therapeutic approaches because it could decrease relapses and metastatic dissemination, which are main causes of mortality in oncology patients. In this work, we discuss the role of these signaling pathways in CSCs along with their therapeutic potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB signaling in inflammation
Liu, T., Zhang, L., Joo, D., & Sun, S.-C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.23 · Cited by 8,791
NF-κB regulation in the immune system
Li, Q., & Verma, I. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri910 · Cited by 4,007
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia
Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, A., Jeltsch, M., Mitchell, C., Alitalo, K., Shima, D., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302047 · Cited by 2,894
Cellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679 · cited 1×
“NF-κB binds to promoters of genes such as IL1B, TNF, and IL6 which cause the secretion of cytokines and chemokines (108).”
BackgroundThe family of five: TIR-domain-containing adaptors in Toll-like receptor signalling
O'Neill, L. A. J., & Bowie, A. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2079 · Cited by 2,667 · cited 1×
“These adaptor proteins include Myd88, TRIF/TICAM-1, TIRAP/Mal, TIRP/TRAM, and SRAM (295, 296).”
BackgroundAssociation of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555
TEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
TAK1 is a ubiquitin-dependent kinase of MKK and IKK
Wang, C., Deng, L., Hong, M., Akkaraju, G. R., Inoue, J.-I., & Chen, Z. J. (2001) · Nature · doi:10.1038/35085597 · Cited by 2,125
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974 · cited 1×
“This situation promotes a tumorigenic microenvironment in colon cancer (116).”
BackgroundYAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879 · cited 1×
“Drugs such as thalidomide and its derivatives act in this way (126, 127).”
BackgroundLiu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S.-J., Anders, R. A., Liu, J. O., & Pan, D. (2012) · Genes & Development · doi:10.1101/gad.192856.112 · Cited by 1,452
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF β-TRCP
Zhao, B., Li, L., Tumaneng, K., Wang, C.-Y., & Guan, K.-L. (2010) · Genes & Development · doi:10.1101/gad.1843810 · Cited by 1,418
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells
Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., Inui, M., Montagner, M., Parenti, A. R., Poletti, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.048 · Cited by 1,381 · cited 12×
“Hippo pathway effectors activated by YAP/TAZ have been shown to induce cancer stem cell (CSC) properties in a wide range of human cancers, including osteosarcoma, glioblastoma, and chemoresistant breast cancer (232, 233).”
BackgroundInfluentialPromotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.007 · Cited by 1,346
Adenoma–linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G.-Y., Österreicher, C. H., Hung, K. E., et al. (2012) · Nature · doi:10.1038/nature11465 · Cited by 1,327
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability
Radisky, D. C., Levy, D. D., Littlepage, L. E., Liu, H., Nelson, C. M., Fata, J. E., Leake, D., Godden, E. L., Albertson, D. G., Angela Nieto, M., et al. (2005) · Nature · doi:10.1038/nature03688 · Cited by 1,284
Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network
Scarpulla, R. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.09.019 · Cited by 1,281
Hedgehog: functions and mechanisms
Varjosalo, M., & Taipale, J. (2008) · Genes & Development · doi:10.1101/gad.1693608 · Cited by 1,217
YAP/TAZ upstream signals and downstream responses
Totaro, A., Panciera, T., & Piccolo, S. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0142-z · Cited by 1,086
Generation of human induced pluripotent stem cells from dermal fibroblasts
Lowry, W. E., Richter, L., Yachechko, R., Pyle, A. D., Tchieu, J., Sridharan, R., Clark, A. T., & Plath, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711983105 · Cited by 1,041
Bray, S. J. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.94 · Cited by 1,012
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986
Telomere length, stem cells and aging
Blasco, M. A. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.38 · Cited by 747
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
Glycolytic Enzymes Can Modulate Cellular Life Span
Kondoh, H., Lleonart, M. E., Gil, J., Wang, J., Degan, P., Peters, G., Martinez, D., Carnero, A., & Beach, D. (2005) · Cancer Research · doi:10.1158/0008-5472.177.65.1 · Cited by 647
Self-citationThe Salvador–Warts–Hippo pathway — an emerging tumour-suppressor network
Harvey, K., & Tapon, N. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2070 · Cited by 628
ROS, stress‐activated kinases and stress signaling in cancer
Benhar, M., Engelberg, D., & Levitzki, A. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf094 · Cited by 600
Zheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9537 · Cited by 588
Dosage‐sensitive requirement for mouse Dll4 in artery development
Duarte, A., Hirashima, M., Benedito, R., Trindade, A., Diniz, P., Bekman, E., Costa, L., Henrique, D., & Rossant, J. (2004) · Genes & Development · doi:10.1101/gad.1239004 · Cited by 563
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551
Liu, C.-Y., Zha, Z.-Y., Zhou, X., Zhang, H., Huang, W., Zhao, D., Li, T., Chan, S. W., Lim, C. J., Hong, W., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.152942 · Cited by 525
Cancer stem cell niche: the place to be
Borovski, T., De Sousa E Melo, F., Vermeulen, L., & Medema, J. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3220 · Cited by 518
Targeting Cancer Stemness in the Clinic: From Hype to Hope
Saygin, C., Matei, D., Majeti, R., Reizes, O., & Lathia, J. D. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.017 · Cited by 517 · cited 1×
“The transition between these states has been reported to be regulated by epigenetic alterations (47).”
BackgroundmiR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response
Mateescu, B., Batista, L., Cardon, M., Gruosso, T., de Feraudy, Y., Mariani, O., Nicolas, A., Meyniel, J.-P., Cottu, P., Sastre-Garau, X., et al. (2011) · Nature Medicine · doi:10.1038/nm.2512 · Cited by 502
Patel, N. S., Li, J.-L., Generali, D., Poulsom, R., Cranston, D. W., & Harris, A. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1208 · Cited by 349
Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway
Chan, P., Han, X., Zheng, B., DeRan, M., Yu, J., Jarugumilli, G. K., Deng, H., Pan, D., Luo, X., & Wu, X. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2036 · Cited by 313
Starnes, C. O. (1992) · Nature · doi:10.1038/357011a0 · Cited by 284 · cited 9×
“There are many pathways that regulate the CSC phenotype and its pluripotency state, providing mechanistic support for acquired drug resistance, including altered metabolism and oxidation states; phenotypic plasticity; increased membrane Frontiers in Oncology | www.frontiersin.org 20 August 2020 | Volume 10 | Article 1…”
BackgroundInfluentialCharacterization of Hippo Pathway Components by Gene Inactivation
Plouffe, S. W., Meng, Z., Lin, K. C., Lin, B., Hong, A. W., Chun, J. V., & Guan, K.-L. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.10.034 · Cited by 275
Hong, D. S., Kurzrock, R., Supko, J. G., He, X., Naing, A., Wheler, J., Lawrence, D., Eder, J. P., Meyer, C. J., Ferguson, D. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2703 · Cited by 236 · cited 1×
“Phase I studies have been conducted for various types of cancer: pancreatic adenocarcinoma (133), solid tumors and lymphomas (134).”
BackgroundBrodowska, K., Al-Moujahed, A., Marmalidou, A., Meyer zu Horste, M., Cichy, J., Miller, J. W., Gragoudas, E., & Vavvas, D. G. (2014) · Experimental Eye Research · doi:10.1016/j.exer.2014.04.011 · Cited by 220
Messersmith, W. A., Shapiro, G. I., Cleary, J. M., Jimeno, A., Dasari, A., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0607 · Cited by 218
Fort, M. M., Mozaffarian, A., Stöver, A. G., Correia, J. D. S., Johnson, D. A., Crane, R. T., Ulevitch, R. J., Persing, D. H., Bielefeldt-Ohmann, H., Probst, P., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6416 · Cited by 216
Kummar, S., O'Sullivan Coyne, G., Do, K. T., Turkbey, B., Meltzer, P. S., Polley, E., Choyke, P. L., Meehan, R., Vilimas, R., Horneffer, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.1994 · Cited by 183
Emerging roles and therapeutic value of exosomes in cancer metastasis
Wu, M., Wang, G., Hu, W., Yao, Y., & Yu, X.-F. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0964-8 · Cited by 140
Ferrarotto, R., Eckhardt, G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J. V., Kapoun, A. M., Xu, L., & Munster, P. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy171 · Cited by 138 · cited 1×
“Brontictuzumab is an anti-Notch1 mAb that is being studied in hematological malignances and advanced solid tumors (phase I) (177, 178) (Table 1).”
BackgroundPapayannidis, C., DeAngelo, D. J., Stock, W., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., English, P. A., Ozeck, M., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.80 · Cited by 122
A Role for NF-κB in Organ Specific Cancer and Cancer Stem Cells
Kaltschmidt, C., Banz-Jansen, C., Benhidjeb, T., Beshay, M., Förster, C., Greiner, J., Hamelmann, E., Jorch, N., Mertzlufft, F., Pfitzenmaier, J., et al. (2019) · Cancers · doi:10.3390/cancers11050655 · Cited by 102
Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis
Pellegrini, P., Cordero, A., Gallego, M. I., Dougall, W. C., Purificación, M., Pujana, M. A., & Gonzalez-Suarez, E. (2013) · Stem Cells · doi:10.1002/stem.1454 · Cited by 52 · cited 1×
“In addition, mammary stem and progenitor cells were expanded by constitutive RANK signaling, and the overexpression of this activator increased tumorigenesis properties (119).”
BackgroundZweidler-McKay, P. A., DeAngelo, D. J., Douer, D., Dombret, H., Ottmann, O. G., Vey, N., Thomas, D. A., Zhu, L., Huang, F., Bajaj, G., et al. (2014) · Blood · doi:10.1182/blood.v124.21.968.968 · Cited by 46
Casulo, C., Ruan, J., Dang, N. H., Gore, L., Diefenbach, C., Beaven, A. W., Castro, J. E., Porcu, P., Faoro, L., Dupont, J., et al. (2016) · Blood · doi:10.1182/blood.v128.22.5108.5108 · Cited by 35
Cited by
Nicotinamide Adenine Dinucleotide (NAD) Metabolism as a Relevant Target in Cancer
Navas, L. E., & Carnero, A. (2022) · Cells · doi:10.3390/cells11172627 · Cited by 68
Self-citationWu, T., Liao, L., Wu, T., Chen, S., Yi, Q., & Xu, M. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2283328 · Cited by 20
Immunogenic cell death mediated TLR3/4-activated MSCs in U87 GBM cell line
Emami Meybodi, S. M., Moradi Moraddahande, F., & Dehghani Firoozabadi, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29858 · Cited by 3
Metadata
- Authors
- Espinosa-Sánchez, A., Suárez-Martínez, E., Sánchez-Díaz, L., & Carnero, A.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-08-26
- Volume
- 10
- Pages
- 1533-1533
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3080816559
- Cited by
- 71
- References
- 52
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.